Your browser doesn't support javascript.
loading
The definition of treatment resistance in anxiety disorders: a Delphi method-based consensus guideline.
Domschke, Katharina; Seuling, Patrik D; Schiele, Miriam A; Bandelow, Borwin; Batelaan, Neeltje M; Bokma, Wicher A; Branchi, Igor; Broich, Karl; Burkauskas, Julius; Davies, Simon J C; Dell'Osso, Bernardo; Fagan, Harry; Fineberg, Naomi A; Furukawa, Toshi A; Hofmann, Stefan G; Hood, Sean; Huneke, Nathan T M; Latas, Milan; Lidbetter, Nicky; Masdrakis, Vasilios; McAllister-Williams, R Hamish; Nardi, Antonio E; Pallanti, Stefano; Penninx, Brenda W J H; Perna, Giampaolo; Pilling, Steve; Pini, Stefano; Reif, Andreas; Seedat, Soraya; Simons, Gemma; Srivastava, Shrikant; Steibliene, Vesta; Stein, Dan J; Stein, Murray B; van Ameringen, Michael; van Balkom, Anton J L M; van der Wee, Nic; Zwanzger, Peter; Baldwin, David S.
Affiliation
  • Domschke K; Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Seuling PD; Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Schiele MA; Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Bandelow B; Department of Psychiatry and Psychotherapy, University Medical Center, Göttingen, Germany.
  • Batelaan NM; Department of Psychiatry and Amsterdam Public Health Research Institute, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands.
  • Bokma WA; Department of Psychiatry and Amsterdam Public Health Research Institute, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands.
  • Branchi I; Center for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, Rome, Italy.
  • Broich K; Federal Institute for Drugs and Medical Devices, Bonn, Germany.
  • Burkauskas J; Laboratory of Behavioral Medicine, Neuroscience Institute, Lithuanian University of Health Sciences, Palanga, Lithuania.
  • Davies SJC; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Dell'Osso B; Centre for Addiction and Mental Health, Toronto, ON, Canada.
  • Fagan H; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
  • Fineberg NA; Department of Mental Health and Addictions, ASST Fatebenefratelli-Sacco, Milan, Italy.
  • Furukawa TA; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Hofmann SG; Southern Health NHS Foundation Trust, Southampton, UK.
  • Hood S; University of Hertfordshire & Hertfordshire Partnership, University NHS Foundation Trust, Hatfield, UK.
  • Huneke NTM; Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.
  • Latas M; Department of Clinical Psychology, Philipps University Marburg, Marburg, Germany.
  • Lidbetter N; Division of Psychiatry, Medical School, University of Western Australia, Perth, WA, Australia.
  • Masdrakis V; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • McAllister-Williams RH; Southern Health NHS Foundation Trust, Southampton, UK.
  • Nardi AE; Clinic for Psychiatry, University Clinical Center of Serbia, Belgrade, Serbia.
  • Pallanti S; Belgrade University School of Medicine, Belgrade, Serbia.
  • Penninx BWJH; Anxiety UK, Manchester, UK.
  • Perna G; First Department of Psychiatry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Pilling S; Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.
  • Pini S; Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust, Newcastle, UK.
  • Reif A; Panic & Respiration Laboratory, Institute of Psychiatry, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Seedat S; Institute of Neuroscience, Florence, Italy.
  • Simons G; Albert Einstein College of Medicine, New York, NY, USA.
  • Srivastava S; Department of Psychiatry and Amsterdam Public Health Research Institute, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands.
  • Steibliene V; Department of Biological Sciences, Humanitas University, Milan, Italy.
  • Stein DJ; Centre for Outcomes Research and Effectiveness, Research Department of Clinical, Educational & Health Psychology, University College London, London, UK.
  • Stein MB; University of Pisa School of Medicine, Pisa, Italy.
  • van Ameringen M; Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • van Balkom AJLM; Fraunhofer Institute for Translational Medicine and Pharmacology, Frankfurt am Main, Germany.
  • van der Wee N; Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Zwanzger P; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Baldwin DS; Solent NHS Trust, Southampton, UK.
World Psychiatry ; 23(1): 113-123, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38214637
ABSTRACT
Anxiety disorders are very prevalent and often persistent mental disorders, with a considerable rate of treatment resistance which requires regulatory clinical trials of innovative therapeutic interventions. However, an explicit definition of treatment-resistant anxiety disorders (TR-AD) informing such trials is currently lacking. We used a Delphi method-based consensus approach to provide internationally agreed, consistent and clinically useful operational criteria for TR-AD in adults. Following a summary of the current state of knowledge based on international guidelines and an available systematic review, a survey of free-text responses to a 29-item questionnaire on relevant aspects of TR-AD, and an online consensus meeting, a panel of 36 multidisciplinary international experts and stakeholders voted anonymously on written statements in three survey rounds. Consensus was defined as ≥75% of the panel agreeing with a statement. The panel agreed on a set of 14 recommendations for the definition of TR-AD, providing detailed operational criteria for resistance to pharmacological and/or psychotherapeutic treatment, as well as a potential staging model. The panel also evaluated further aspects regarding epidemiological subgroups, comorbidities and biographical factors, the terminology of TR-AD vs. "difficult-to-treat" anxiety disorders, preferences and attitudes of persons with these disorders, and future research directions. This Delphi method-based consensus on operational criteria for TR-AD is expected to serve as a systematic, consistent and practical clinical guideline to aid in designing future mechanistic studies and facilitate clinical trials for regulatory purposes. This effort could ultimately lead to the development of more effective evidence-based stepped-care treatment algorithms for patients with anxiety disorders.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies / Qualitative_research Language: En Journal: World Psychiatry Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies / Qualitative_research Language: En Journal: World Psychiatry Year: 2024 Document type: Article